ROS1 in NSCLC
ROS1-Alterations and Molecular Testing in Advanced NSCLC

Released: August 29, 2024

Expiration: August 28, 2025

Jessica J Lin
Jessica J Lin, MD
Alice Shaw
Alice Shaw, MD, PhD

Activity

Progress
1
Course Completed

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

  • ROS1-gene fusions in advanced lung cancer
  • ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
  • Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
  • Advantages of RNA- vs DNA-based next-generation sequencing